Author:
Yang Ye,Huang Lei,Gao Jie,Qian Bingjun
Funder
Natural Science Foundation of the Jiangsu Higher Education Institutions of China
Jiangsu Provincial Health Commission of China
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044.
2. Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta. 2021;1876(2):188636.
3. Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12(1):14–6.
4. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–56.
5. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1419–28.